Last reviewed · How we verify
Decitabine combined with HAAG Regimen
Decitabine combined with HAAG Regimen is a Hypomethylating agent combined with chemotherapy regimen Small molecule drug developed by The First Affiliated Hospital of Soochow University. It is currently in Phase 3 development for Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients, Myelodysplastic syndrome (MDS).
Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies.
Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies. Used for Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients, Myelodysplastic syndrome (MDS).
At a glance
| Generic name | Decitabine combined with HAAG Regimen |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Hypomethylating agent combined with chemotherapy regimen |
| Target | DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Decitabine is a hypomethylating agent that removes aberrant DNA methylation marks on tumor suppressor genes, restoring their expression and inducing differentiation and apoptosis in leukemic cells. The HAAG regimen provides intensive chemotherapy with multiple mechanisms of action. Together, this combination targets both epigenetic dysregulation and provides direct cytotoxic activity against leukemic blasts.
Approved indications
- Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients
- Myelodysplastic syndrome (MDS)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Nausea and vomiting
- Mucositis
- Hepatotoxicity
- Tumor lysis syndrome
Key clinical trials
- Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients (PHASE3)
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients (PHASE3)
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decitabine combined with HAAG Regimen CI brief — competitive landscape report
- Decitabine combined with HAAG Regimen updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI
Frequently asked questions about Decitabine combined with HAAG Regimen
What is Decitabine combined with HAAG Regimen?
How does Decitabine combined with HAAG Regimen work?
What is Decitabine combined with HAAG Regimen used for?
Who makes Decitabine combined with HAAG Regimen?
What drug class is Decitabine combined with HAAG Regimen in?
What development phase is Decitabine combined with HAAG Regimen in?
What are the side effects of Decitabine combined with HAAG Regimen?
What does Decitabine combined with HAAG Regimen target?
Related
- Drug class: All Hypomethylating agent combined with chemotherapy regimen drugs
- Target: All drugs targeting DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis
- Manufacturer: The First Affiliated Hospital of Soochow University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML), particularly in elderly or relapsed/refractory patients
- Indication: Drugs for Myelodysplastic syndrome (MDS)